Arrowhead Pharma (ARWR) 5.86 $ARWR Arrowhead

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Arrowhead Pharma (ARWR) 5.86 $ARWR

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Third Quarter Results
BusinessWire - Mon Aug 01, 3:01PM CDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, August 9, 2016, at 4:30 p.m. EDT to discuss its financial results for the fiscal 2016 third quarter ended June 30, 2016. Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and enter Conference ID 57990579.
ARWR: 5.86 (-0.10)

Arrowhead Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
BusinessWire - Wed Jul 06, 6:30AM CDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that president and chief executive officer Christopher Anzalone, Ph.D., will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on July 13, 2016 at 10:45 a.m. EDT in New York.
ARWR: 5.86 (-0.10)

Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B Candidate ARC-521
BusinessWire - Thu Jun 09, 6:30AM CDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 1/2 study of ARC-521, the company's second RNAi-based investigational medicine for the treatment of chronic hepatitis B virus (HBV) infection. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single doses of ARC-521 in healthy volunteers and the safety, tolerability, and antiviral activity of single and multiple doses of ARC-521 in patients with chronic HBV. This study may have multiple readouts, including single dose safety data, single dose antiviral activity data, and multiple dose safety and antiviral activity data.
ARWR: 5.86 (-0.10)

Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Fri Jun 03, 6:30AM CDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that chief operating officer and head of R&D Bruce Given, M.D., will present at the Jefferies 2016 Healthcare Conference on June 10, 2016 at 10:30 a.m. EDT. Investors may access live and archived versions of the audio webcast of this presentation on the Events and Presentations page under the Investors section of the Arrowhead website.
ARWR: 5.86 (-0.10)

How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics
PR Newswire - Thu May 26, 7:50AM CDT
Despite the volatility that continues to envelop the Biotech industry, investors see value in this space. Today's pre-market research on ActiveWallSt.com directs the investor community's focus on the following Healthcare equities: Radius Health Inc. (NASDAQ: RDUS), Cerus Corp. (NASDAQ: CERS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). Register with us today for these stock technical briefings at:
CERS: 7.31 (-0.08), RDUS: 47.01 (-0.11), ARWR: 5.86 (-0.10), FPRX: 51.57 (+0.88)

Arrowhead Research Shares Up 20.5% Since SmarTrend's Buy Recommendation (ARWR)
Comtex SmarTrend(R) - Mon May 16, 1:43PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 3 months, Arrowhead Research has returned 20.51% as of today's recent price of $5.17.
ARWR: 5.86 (-0.10)

Arrowhead Reports Fiscal 2016 Second Quarter Results
BusinessWire - Tue May 10, 3:01PM CDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 second quarter ended March 31, 2016. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.
ARWR: 5.86 (-0.10)

Uptrend Call Working As Arrowhead Research Stock Rises 33.8% (ARWR)
Comtex SmarTrend(R) - Mon May 09, 1:38PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 2 months, Arrowhead Research has returned 33.80% as of today's recent price of $5.74.
ARWR: 5.86 (-0.10)

Arrowhead Pharmaceuticals' Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration
BusinessWire - Fri May 06, 11:00AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented a poster on ARC-LPA, its preclinical development program targeting lipoprotein (a), or Lp(a), for the treatment of cardiovascular disease at the Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease (ATVB|PVD) 2016 Scientific Sessions in Nashville. ARC-LPA is the first RNAi therapeutic program to use Arrowhead's new delivery vehicles designed for subcutaneous (SQ) administration.
ARWR: 5.86 (-0.10)

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Second Quarter Results
BusinessWire - Tue May 03, 3:01PM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, May 10, 2016, at 4:30 p.m. EDT to discuss its financial results for the fiscal 2016 second quarter ended March 31, 2016. Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and enter Conference ID 5054757.
ARWR: 5.86 (-0.10)

34.3% Return Seen to Date on SmarTrend Arrowhead Research Call (ARWR)
Comtex SmarTrend(R) - Fri Apr 29, 1:18PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 2 months, Arrowhead Research has returned 34.27% as of today's recent price of $5.76.
ARWR: 5.86 (-0.10)

Arrowhead Pharmaceuticals to Present at Upcoming May Conferences
BusinessWire - Fri Apr 29, 6:30AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming events.
ARWR: 5.86 (-0.10)

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521
BusinessWire - Thu Apr 28, 6:30AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), recently filed a regulatory submission in New Zealand to begin a Phase 1/2 clinical trial of ARC-521, its RNAi-based therapeutic candidate for the treatment of chronic hepatitis B virus (HBV) infection. Pending approval, Arrowhead intends to proceed with ARC521-1001, a first-in-human study to assess single and multiple-doses of ARC-521 in healthy volunteers and HBV patients.
ARWR: 5.86 (-0.10)

Can Arrowhead Do For Hep B What Gilead Sciences Did For Hep C?
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 25, 5:01PM CDT
SOURCE: ARROWHEAD PHARMA Arrowhead Pharmaceuticals recently offered up insight into potential efficacy for its clinical-stage hepatitis B drug ARC-520 that suggest it may offer the best chance yet at a functional cure for hepatitis B, a common...
GILD: 80.46 (+0.99), ARWR: 5.86 (-0.10), BMY: 76.19 (+1.38)

Arrowhead Research Has Returned 42.9% Since SmarTrend Recommendation (ARWR)
Comtex SmarTrend(R) - Fri Apr 22, 12:23AM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 2 months, Arrowhead Research has returned 42.89% as of today's recent price of $6.13.
ARWR: 5.86 (-0.10)

Arrowhead Research Up 39.4% Since SmarTrend Uptrend Call (ARWR)
Comtex SmarTrend(R) - Thu Apr 14, 12:53PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 1 month, Arrowhead Research has returned 39.39% as of today's recent price of $5.98.
ARWR: 5.86 (-0.10)

4 Hot Trending Small Cap Stocks That You Haven't Heard About
ACCESSWIRE - Thu Apr 14, 8:57AM CDT
NEW YORK, NY / ACCESSWIRE / April 14, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SPWH, CONN, PEG and ARWR are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
ARWR: 5.86 (-0.10), PEG: 45.39 (-0.62), CONN: 6.96 (-0.15), SPWH: 10.06 (-0.12)

Better Buy: Inovio Pharmaceuticals or Arrowhead Research Corp.?
Keith Speights, The Motley Fool - Motley Fool - Thu Apr 14, 8:21AM CDT
Image source: Inovio Pharmaceuticals. Biotech investors have been a sad bunch lately. Politicians slamming high drug prices combined with general market uncertainties have clobbered many biotech stocks over the last several months. Arrowhead...
INO: 10.42 (+0.54), GILD: 80.46 (+0.99), ARWR: 5.86 (-0.10)

What Caused Arrowhead Pharmaceuticals to Skyrocket 13% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 13, 3:58PM CDT
Image source: Arrowhead Pharmaceuticals. What:  After reporting data from an early-stage study of its ARC-520 in hepatitis B patients, shares of  Arrowhead Pharmaceuticals   shot 12.9% higher today. So what: The clinical-stage researcher of...
ARWR: 5.86 (-0.10), BMY: 76.19 (+1.38)

Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data at The International Liver Congress(TM) 2016
BusinessWire - Wed Apr 13, 6:30AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that three presentations are being made on ARC-520, its investigational medicine for the treatment of chronic hepatitis B infection, at The International Liver Congress(TM) 2016 (ILC 2016), in Barcelona, Spain, April 13-17, 2016.
ARWR: 5.86 (-0.10)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Qonto's Banking License Raises the Stakes in Europe

Updated Category News Views 70

A regulatory stamp can look dull on paper, yet this one changes the machinery underneath Qonto. The Paris-based finance platform has received a Credit Institution license from France's ACPR and the European Central Bank, giving it a route to offer broader lending and savings products directly to small and midsize businesses across Europe. That is a serious corporate...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 16

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
FP Markets Puts Anthropic CFD Into the AI Trading Mix

Updated Category News Views 10

A fresh AI bellwether is about to meet the CFD crowd. FP Markets says it will add an Anthropic share CFD, identified as ANT.xnas, to its lineup on November 19, 2026. Clients worldwide are slated to access it through MetaTrader 5, cTrader, and TradingView. That is a tidy distribution expansion, but it lands with the usual AI-market fireworks already hissing in the...

Continue Reading
ActivTrak's Fast 500 Rank Needs Investor Perspective

Updated Category News Views 6

Rank 488 is the sort of trophy that deserves a raised eyebrow, not confetti. ActivTrak made Deloitte's 2026 Technology Fast 500 after posting 101.1% revenue growth from 2022 through 2025, its sixth appearance on the list since 2020. That is real progress, and repeat recognition says this was not a one-quarter sugar high. Still, a Fast 500 ranking is a growth screen, not a...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 228

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 49

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 56

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 91

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading

Top 5 Most Recently Viewed Articles

Embracing Harmony and Cooperation in Today's World

Updated Category News Views 99

Understanding the Essence of Hehe Culture The concept of "Hehe" in Chinese culture symbolizes harmony, peace, and cooperation, deeply embedded in the collective mindset. This philosophy, with roots extending over thousands of years, emphasizes living in balance not only with one another but also with nature and oneself. The teachings of Hehe are particularly significant...

Continue Reading
Current Trends in Mortgage Rates and Home Buying Activity

Updated Category News Views 184

The average rate for a 30-year fixed-rate mortgage dropped to 6.08% in 2024, hitting its lowest point in two years. This slight decrease from 6.09% the previous week caught the eye of potential home buyers and homeowners considering refinancing. In contrast, the average rate for a 15-year mortgage ticked up by a single basis point to reach 5.16%. These small fluctuations...

Continue Reading
Mueller Water Products Engages at 2024 Baird Industrial Conference

Updated Category News Views 195

Mueller Water Products to Engage in the Baird Industrial Conference Mueller Water Products, Inc. (NYSE: MWA), headquartered in Atlanta, is set to participate in the Baird 2024 Global Industrial Conference. This prestigious event will take place in a vibrant city known for its industrial drive and innovation. Mueller’s management team is looking forward to sharing...

Continue Reading
SANY Showcases Advanced Eco-Friendly Solutions at bauma

Updated Category News Views 389

SANY Showcases Advanced Eco-Friendly Solutions at bauma The 34th bauma, recognized as the world's leading trade fair for construction machinery, recently wrapped up in Munich. This year's theme was "The World of Efficiency, Your Partner to Create the Best", and SANY Group, in collaboration with Putzmeister, put forth an impressive display of cutting-edge technology and...

Continue Reading
Orbit International Corp Completes $1 Million Power Supply Order

Updated Category News Views 182

Orbit International Corp Secures Major Follow-On Order Orbit International Corp. (OTCID Basic Market: ORBT), a prominent player in electronic manufacturing and software solutions, has announced the receipt of a new order valued at approximately $1,000,000. This order, secured by its Orbit Power Group (OPG), pertains to a commercial power supply that is utilized in...

Continue Reading